NCT04824261 is a NA clinical trial of Clotrimazol solution 1% in Otomycosis, sponsored by Assiut University.

Who is sponsoring NCT04824261?

NCT04824261 is sponsored by Assiut University.

What drugs are being tested in NCT04824261?

Interventions in NCT04824261: Clotrimazol solution 1%, 4%boric acid in distilled water.

What condition does NCT04824261 study?

NCT04824261 studies Otomycosis.

Is NCT04824261 still recruiting?

NCT04824261 is currently status unknown. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT04824261

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of 4% Boric Acid in Distilled Water Versus Clotrimazole Solution in Otomycosis Patients.

Status unknown NA Last updated 1 April 2021

What this trial tests

NA trial testing Clotrimazol solution 1% in Otomycosis in 100 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
31 May 2022

1 June 2023

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 June 2021
Primary completion	31 May 2022
Estimated completion	1 June 2023

Drugs / interventions tested

Clotrimazol solution 1% — full drug profile →
4%boric acid in distilled water — full drug profile →

Conditions studied

Otomycosis — all drugs for Otomycosis →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Otomycosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Otomycosis is a fungal infection that affects one, or occasionally both, of the ears. It mostly affects people who live in warm or tropical areas. It also often affects people who swim frequently, live with diabetes, or have other chronic medical and skin conditions. It is a pathologic entity, with candida and aspergillus the most common fungal species. \]Various predisposing factors include a humid climate, presence of cerumen, instrumentation of the ear, increased use of topical antibiotics / steroid preparations, immune-compromised host, patients who have undergone open cavity mastoidectomy and those who wear hearing aids with occlusive ear mold. The infection is usually unilateral and characterized by inflammatory pruritis, scaling and otalgia.Treatment recommendations have included local debridement, local and systemic antifungal agents and discontinuation of topical antibiotics. Sometimes otomycosis presents as a challenging disease for its long term treatment and follow up, yet its recurrence rate remains high. According to Thai National List of essential medicines for topical antifugal agents are: * acetic acid (2% in aqueous and 2% in 70% isopropyl alcohol) * boric acid (4% in distilled water) * gentian violet * clotrimazole ear drop. Some fungal infections such as Aspergillus may be resistant to the usual ear drops. They may require oral medications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Otomycosis

Currently open trials in the same condition.

NCT06530069 — Exploring the Risk Factors of Otomycosis: A Case-Control Study · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04824261 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04824261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing